Sima Jeha1, Kristine R Crews2, Deqing Pei3, Melissa Peyton4, John C Panetta2, Raul C Ribeiro1, Xujie Zhao2, Patrick Campbell1, Monika L Metzger1, Jun J Yang2, Cheng Cheng3, Ching-Hon Pui1, Deepa Bhojwani5,6. 1. Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee. 2. Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee. 3. Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, Tennessee. 4. Cancer Center Administration, St. Jude Children's Research Hospital, Memphis, Tennessee. 5. Children's Hospital Los Angeles, Los Angeles, California. 6. Keck School of Medicine, University of Southern California, Los Angeles, California.
Abstract
BACKGROUND: A phase 1 study was conducted to determine the maximum tolerated dose of bendamustine when given in combination with clofarabine, etoposide, and dexamethasone daily for 5 days in children and adolescents with relapsed or refractory hematologic malignancies. METHODS: Patients younger than 22 years with second or greater relapsed or refractory acute leukemia or lymphoma after 2 or more prior regimens were eligible. With the rolling 6 design, participants received escalating doses of bendamustine (30, 40, or 60 mg/m2 /d) in combination with clofarabine (40 mg/m2 ), etoposide (100 mg/m2 ), and dexamethasone (8 mg/m2 ) daily for 5 days. Optional pharmacokinetic studies were performed in cycle 1 on day 1 and day 5. RESULTS: Sixteen patients were enrolled. Six patients were treated at the dose level of 30 mg/m2 /d, 6 were treated at the dose level of 40 mg/m2 /d, and 4 were treated at the dose level of 60 mg/m2 /d. The dose-limiting toxicity was prolonged myelosuppression. The combination was otherwise well tolerated. The recommended dose of bendamustine in this combination was 30 mg/m2 /d for 5 days. Ten responses were observed after 1 cycle: 6 complete remissions, 1 durable minimal residual disease-negative complete remission without platelet recovery in a patient with early T-cell precursor leukemia, and 3 partial remissions. Six patients proceeded to transplantation. The event-free survival rate was 40.6% (95% confidence interval [CI], 17.5%-63.7%) at 1 year and 33.9% (95% CI, 11.9%-55.9%) at 3 years. CONCLUSIONS: Bendamustine is well tolerated in combination with clofarabine, etoposide, and dexamethasone. The combination administered over 5 days is effective for multiple relapsed and refractory hematologic malignancies. This trial is registered with ClinicalTrials.gov (NCT01900509). LAY SUMMARY: Improvements to the existing chemotherapy regimen are still needed for patients who relapse after targeted therapies and immunotherapies and for those who are not eligible for or have no access to such therapies. A regimen combining cyclophosphamide, clofarabine, and etoposide has been used in relapsed and refractory pediatric patients with hematologic malignancies. This study shows that substituting bendamustine for cyclophosphamide in combination with clofarabine and etoposide is safe and effective.
BACKGROUND: A phase 1 study was conducted to determine the maximum tolerated dose of bendamustine when given in combination with clofarabine, etoposide, and dexamethasone daily for 5 days in children and adolescents with relapsed or refractory hematologic malignancies. METHODS: Patients younger than 22 years with second or greater relapsed or refractory acute leukemia or lymphoma after 2 or more prior regimens were eligible. With the rolling 6 design, participants received escalating doses of bendamustine (30, 40, or 60 mg/m2 /d) in combination with clofarabine (40 mg/m2 ), etoposide (100 mg/m2 ), and dexamethasone (8 mg/m2 ) daily for 5 days. Optional pharmacokinetic studies were performed in cycle 1 on day 1 and day 5. RESULTS: Sixteen patients were enrolled. Six patients were treated at the dose level of 30 mg/m2 /d, 6 were treated at the dose level of 40 mg/m2 /d, and 4 were treated at the dose level of 60 mg/m2 /d. The dose-limiting toxicity was prolonged myelosuppression. The combination was otherwise well tolerated. The recommended dose of bendamustine in this combination was 30 mg/m2 /d for 5 days. Ten responses were observed after 1 cycle: 6 complete remissions, 1 durable minimal residual disease-negative complete remission without platelet recovery in a patient with early T-cell precursor leukemia, and 3 partial remissions. Six patients proceeded to transplantation. The event-free survival rate was 40.6% (95% confidence interval [CI], 17.5%-63.7%) at 1 year and 33.9% (95% CI, 11.9%-55.9%) at 3 years. CONCLUSIONS: Bendamustine is well tolerated in combination with clofarabine, etoposide, and dexamethasone. The combination administered over 5 days is effective for multiple relapsed and refractory hematologic malignancies. This trial is registered with ClinicalTrials.gov (NCT01900509). LAY SUMMARY: Improvements to the existing chemotherapy regimen are still needed for patients who relapse after targeted therapies and immunotherapies and for those who are not eligible for or have no access to such therapies. A regimen combining cyclophosphamide, clofarabine, and etoposide has been used in relapsed and refractory pediatric patients with hematologic malignancies. This study shows that substituting bendamustine for cyclophosphamide in combination with clofarabine and etoposide is safe and effective.
Authors: Hiroto Inaba; Deepa Bhojwani; Jennifer L Pauley; Deqing Pei; Cheng Cheng; Monika L Metzger; Scott C Howard; Jeffrey E Rubnitz; John T Sandlund; Raul C Ribeiro; Wing Leung; Dario Campana; Ching-Hon Pui; Sima Jeha Journal: Br J Haematol Date: 2011-08-25 Impact factor: 6.998
Authors: A C Dubbelman; M Tibben; H Rosing; A Gebretensae; L Nan; S H Gorman; P Robertson; J H M Schellens; J H Beijnen Journal: J Chromatogr B Analyt Technol Biomed Life Sci Date: 2012-03-03 Impact factor: 3.205
Authors: Joel S Owen; Murad Melhem; Julie A Passarell; Denise D'Andrea; Mona Darwish; Bradley Kahl Journal: Cancer Chemother Pharmacol Date: 2010-02-06 Impact factor: 3.333
Authors: Alison J Moskowitz; Paul A Hamlin; Miguel-Angel Perales; John Gerecitano; Steven M Horwitz; Matthew J Matasar; Ariela Noy; Maria Lia Palomba; Carol S Portlock; David J Straus; Tricia Graustein; Andrew D Zelenetz; Craig H Moskowitz Journal: J Clin Oncol Date: 2012-12-17 Impact factor: 44.544
Authors: Kirsten Fischer; Paula Cramer; Raymonde Busch; Sebastian Böttcher; Jasmin Bahlo; Jöerg Schubert; Karl H Pflüger; Silke Schott; Valentin Goede; Susanne Isfort; Julia von Tresckow; Anna-Maria Fink; Andreas Bühler; Dirk Winkler; Karl-Anton Kreuzer; Peter Staib; Matthias Ritgen; Michael Kneba; Hartmut Döhner; Barbara F Eichhorst; Michael Hallek; Stephan Stilgenbauer; Clemens-Martin Wendtner Journal: J Clin Oncol Date: 2012-08-06 Impact factor: 44.544
Authors: Jonathan W Friedberg; Philip Cohen; Ling Chen; K Sue Robinson; Andres Forero-Torres; Ann S La Casce; Luis E Fayad; Alberto Bessudo; Elber S Camacho; Michael E Williams; Richard H van der Jagt; Jennifer W Oliver; Bruce D Cheson Journal: J Clin Oncol Date: 2008-01-10 Impact factor: 44.544
Authors: R Peto; M C Pike; P Armitage; N E Breslow; D R Cox; S V Howard; N Mantel; K McPherson; J Peto; P G Smith Journal: Br J Cancer Date: 1977-01 Impact factor: 7.640